Dr. Christopher K. Lippincott, M.D.
Internal Medicine (Internal Medicine Physician)
600 N Wolfe St, Brady 522b
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 236
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Virginia School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MD license D79961 -
Infectious Disease Physician
MD license D79961
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Johns Hopkins Bayview Medical Center Baltimore, MD
- Beebe Medical Center Lewes, DE
- Sibley Memorial Hospital Washington, DC
- Tidalhealth Peninsula Regional, Inc Salisbury, MD
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 236
- Services billed
- 803
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 145 | 89 |
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 84 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 80 | 77 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 78 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 40 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 36 | 36 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 19 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ethambutol Hcl | 66 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 43 |
| Azithromycin Other prescribers in Baltimore, MD | 40 |
| Arikayce (amikacin liposomal/neb.accessr) | 38 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Baltimore, MD | 28 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Baltimore, MD | 28 |
| Nuzyra (omadacycline tosylate) | 27 |
| Dovato (dolutegravir sodium/lamivudine) | 22 |
| Tivicay (dolutegravir sodium) | 22 |
| Rosuvastatin Calcium Other prescribers in Baltimore, MD | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 17 payments worth $16,699 in total to this clinician.
| Paratek Pharmaceuticals, Inc. | $9,020 |
|---|---|
| Insmed, Inc. | $7,679 |
| Consulting Fee | $13,760 |
|---|---|
| Travel and Lodging | $2,244 |
| Food and Beverage | $695 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. May 20, 2025 | Consulting Fee NUZYRA · ANTIBIOTIC | $7,910 |
| Insmed, Inc. May 8, 2025 | Consulting Fee | $5,850 |
| Insmed, Inc. Mar 28, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $852 |
| Paratek Pharmaceuticals, Inc. May 20, 2025 | Travel and Lodging NUZYRA · ANTIBIOTIC · travel to DENVER, CO | $436 |
| Insmed, Inc. Apr 4, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $347 |
| Paratek Pharmaceuticals, Inc. Apr 7, 2025 | Travel and Lodging NUZYRA · ANTIBIOTIC · travel to DENVER, CO · in-kind | $288 |
| Insmed, Inc. Apr 7, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $193 |
| Insmed, Inc. Apr 8, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $128 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $39,640 in research payments for these studies, mostly to the institutions running them.
- Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Paratek Pharmaceuticals, Inc. · Completed · NCT04922554
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.